Apex Biotechnology Corp. (TPE:1733)
Taiwan
· Delayed Price · Currency is TWD 32.00
-0.05 (-0.16%)
Apr 29, 2025, 1:30 PM CST
Apex Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 128 | 115.78 | 181.79 | 202.22 | 94.8 | Upgrade
|
| Depreciation & Amortization | 63.41 | 74.19 | 92.71 | 94.32 | 103.55 | Upgrade
|
| Other Amortization | 1.4 | 1.52 | 1.39 | 1.35 | 1.65 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 17.78 | 6 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -4.23 | 3.96 | 29.48 | -31.7 | -6.8 | Upgrade
|
| Stock-Based Compensation | - | - | - | 1.59 | - | Upgrade
|
| Provision & Write-off of Bad Debts | 0.05 | 1.82 | - | -3.5 | -0.36 | Upgrade
|
| Other Operating Activities | -11.24 | 10.85 | -45.74 | 33.62 | 11.46 | Upgrade
|
| Change in Accounts Receivable | -58.6 | 188.87 | -1.38 | -160.77 | 110.14 | Upgrade
|
| Change in Inventory | 67.61 | -17.96 | -116.67 | -136.05 | -9 | Upgrade
|
| Change in Accounts Payable | 67.96 | -96.22 | -59.51 | 99.31 | -30.54 | Upgrade
|
| Change in Unearned Revenue | 51.68 | -22.45 | -64.02 | 50.45 | 21.84 | Upgrade
|
| Change in Other Net Operating Assets | 22.64 | -47.74 | 2.56 | 29.02 | -16.13 | Upgrade
|
| Operating Cash Flow | 328.67 | 230.39 | 26.62 | 179.87 | 280.6 | Upgrade
|
| Operating Cash Flow Growth | 42.66% | 765.61% | -85.20% | -35.90% | -39.33% | Upgrade
|
| Capital Expenditures | -28.24 | -21.91 | -36.58 | -26.59 | -45.25 | Upgrade
|
| Sale (Purchase) of Intangibles | -1.39 | -3.07 | -4.07 | -3.6 | -3.07 | Upgrade
|
| Investment in Securities | - | - | -0.7 | -2 | 123.19 | Upgrade
|
| Other Investing Activities | -5.96 | 2.48 | -0.01 | -2.83 | 3.97 | Upgrade
|
| Investing Cash Flow | -35.6 | -22.5 | -41.37 | -35.02 | 78.83 | Upgrade
|
| Short-Term Debt Issued | 29.45 | 281.16 | 964.61 | 1,690 | 200 | Upgrade
|
| Total Debt Issued | 29.45 | 281.16 | 964.61 | 1,690 | 200 | Upgrade
|
| Short-Term Debt Repaid | -59.45 | -301.16 | -1,065 | -1,540 | -297.51 | Upgrade
|
| Long-Term Debt Repaid | -8.7 | -8.2 | -7.68 | -404.2 | -5.51 | Upgrade
|
| Total Debt Repaid | -68.15 | -309.35 | -1,072 | -1,944 | -303.02 | Upgrade
|
| Net Debt Issued (Repaid) | -38.7 | -28.2 | -107.68 | -254.2 | -103.02 | Upgrade
|
| Issuance of Common Stock | - | - | - | 12.25 | - | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | -12.25 | Upgrade
|
| Common Dividends Paid | -109.95 | -139.93 | -129.94 | -109.32 | -109.95 | Upgrade
|
| Other Financing Activities | -0.03 | -0.02 | 0.01 | -0.01 | 0.36 | Upgrade
|
| Financing Cash Flow | -148.67 | -168.14 | -237.6 | -351.27 | -224.85 | Upgrade
|
| Foreign Exchange Rate Adjustments | 6.24 | 10.59 | 28.72 | -25.19 | -1.34 | Upgrade
|
| Net Cash Flow | 150.64 | 50.34 | -223.63 | -231.61 | 133.25 | Upgrade
|
| Free Cash Flow | 300.43 | 208.48 | -9.97 | 153.28 | 235.35 | Upgrade
|
| Free Cash Flow Growth | 44.10% | - | - | -34.87% | -42.23% | Upgrade
|
| Free Cash Flow Margin | 16.22% | 12.44% | -0.44% | 7.19% | 11.74% | Upgrade
|
| Free Cash Flow Per Share | 2.99 | 2.08 | -0.10 | 1.45 | 2.08 | Upgrade
|
| Cash Interest Paid | 3.64 | 4.39 | 5.4 | 4.7 | 5.45 | Upgrade
|
| Cash Income Tax Paid | 48.43 | 18.9 | 24.04 | 9.19 | 29.54 | Upgrade
|
| Levered Free Cash Flow | 254.23 | 164.39 | -78.18 | 55.06 | 199.12 | Upgrade
|
| Unlevered Free Cash Flow | 256.51 | 167.14 | -74.81 | 62.89 | 205.54 | Upgrade
|
| Change in Net Working Capital | -141.05 | -27.83 | 238.61 | 132.28 | -84.09 | Upgrade
|
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.